The activation of thrombin-treated endothelial cells
resulted in
disruption of the vascular tissues. A novel oyster-derived bioactive
dodecapeptide (IEELEELEAER, P-2-CG) was reported to protect the human
umbilical vein endothelial cells and their barrier function via the
decrease of VE-cadherin disruption and the restoration of the F-actin
arrangement. The promotion of the extrinsic pathway in this case triggers
the release of tissue factors that occurs on the surface of the endothelial
cells, thus changing the antithrombotic to prothrombotic. P-2-CG induced
accordingly a prolongation of plasma clotting time and thrombin generation
time, following the alteration of the antithrombotic phenotype. Furthermore,
the antithrombotic activity of P-2-CG was also supported by the reduction
of FXa and the inhibition of other factors release, for instance,
inflammation factors, ROS, etc. In addition to its antithrombogenic
role, P-2-CG displayed anti-inflammatory and antioxidant properties
via the mitogen-activated protein kinase cascades and central signaling
pathways as shown in an in vitro model of endothelial
dysfunction.